TAO: Otamixaban disappoints in NSTE-ACS

The new IV factor Xa inhibitor was not superior to heparin plus eptifibatide in reducing death/MI but did increase bleeding among patients with NSTE-ACS and a planned invasive strategy.
Source: theHeart.org - Category: Cardiology Source Type: news